Bayer AG
BAYGn.EU
$28.86
Closing
▼-0.28%
1D
▼-20.03%
YTD
Market cap
$28.26B
52 week high
$64.71
52 week low
$26.78
Volume
3,533,816
Check if the stock is halal
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $3.99/month
Market cap
$28.26B
Analysts' Rating
BUY
Price Target (Mean)
56.1206804
Total Analysts
7
P/E
Operating Margin
-34.75%
Beta
1.05
Revenue Growth (Annual)
2.52%
52 week high
$64.71
52 week low
$26.78
Div. Yield
0.41%
EPS Annual Growth
137.24
Note on Purification and Zakat
- Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly).
- If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
- For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them.
Company Profile
Bayer AG is a German-based life science company. The Company’s segments are Pharmaceuticala and Consumer Health. The Pharmaceuticals segment focuses on researching, developing and marketing prescription products and specialty therapeutics especially in the areas of cardiology, oncology, gynecology, hematology and ophthalmology, as well as radiopharmacology and others. The Company is focusing on their oncology platform for Targeted Alpha Therapies for treating prostate cancer. The Consumer Health segment develops, produces and markets nonprescription over-the-counter products in the dermatology, dietary supplement, analgesic, gastrointestinal, cold, allergy, sinus and flu, foot care and sun protection categories, among others. The Crop Science segment has been moved to Cinven which operates as an independent company called Envu.
